ReviewPrzeglad gastroenterologiczny2026
Metastatic Crohn's disease unmasked: from elusive skin clues to diagnosis and treatment - a comprehensive review.
Review in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic Crohn's disease (MCD) is the rarest yet one of the most disabling cutaneous manifestations of inflammatory bowel disease. Granulomatous lesions frequently mimic infections, autoimmune dermatoses, or drug reactions, causing delayed diagnosis and substantial psychosocial burden. Its true incidence is probably underestimated, as lesions may precede, accompany, or follow intestinal Crohn's disease and often arise in intimate locations. This review synthesises current knowledge on epidemiology, pathogenesis, and clinical-histological features, emphasising emerging mechanisms such as dysregulated Th17/IL-23/TNF-α signalling, NOD2 variants, epitope spreading, and aberrant T-cell homing. We present the 2025 Delphi diagnostic criteria for oral and genital/other MCD and concise differential-diagnosis frameworks. Treatment evidence is summarised from topical and systemic therapies to biologics, IL-23 inhibitors, and JAK blockade. Finally, we introduce DUET-MCD, a 24-month stepwise dermatology - gastroenterology management scheme designed to standardise care and reduce diagnostic delay - prompting the question of how many "refractory" dermatoses represent unrecognised MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.